A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment

Environmental Health Perspectives

Volumn 110, Issue 1, 2002, Pages 85-93

  Clewell III, Harvey J ^a   Andersen, Melvin E ^b   Barton, Hugh A ^c  

^a ENVIRON INTERNATIONAL CORPORATION   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Dose response assessment; Interspecies extrapolation; Pharmacokinetics; Physiologically based pharmacokinetic modeling; Risk assessment; Tissue dosimetry

Indexed keywords

ENVIRONMENTAL CHEMICAL;

ANIMAL EXPERIMENT; ARTICLE; CANCER MODEL; CANCER RISK; CONTROLLED STUDY; DOSIMETRY; ENVIRONMENTAL EXPOSURE; HUMAN; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RAT; RELIABILITY; RISK ASSESSMENT; SPECIES DIFFERENCE; TOXICOKINETICS; TOXICOLOGY;

ANIMALIA;

EID: 0036151312     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.0211085     Document Type: Article

References (55)

1. Risk assessment extrapolations and physiological modeling
2. Biologically motivated models for chemical risk assessment
3. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors
4. Deposition and retention modeling of inhaled cadmium in rat and human lung: An example for extrapolation of effects and risk estimation
5. Equivalent oral and inhalation exposure to cadmium compounds: Risk estimation based on route-to-route extrapolation
6. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
7. Occupational exposure to methylene chloride; final rule
8. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model
9. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans
10. Limiting the uncertainty in risk assessment by the development of physiologically based pharmacokinetic and pharmacodynamic models
11. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances
12. Incorporating biological information in quantitative risk assessment: An example with methylene chloride
13. Development of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment
14. A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment
15. Incorporation of pharmacokinetics in noncancer risk assessment: Example with chloropentafluorobenzene
16. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment
17. Evaluating noncancer effects of trichloroethylene: Dosimetry, mode of action, and risk assessment
18. Principles of Route-to-Route Extrapolation for Risk Assessment
19. Risk assessment of chemical mixtures: Biological and toxicologic issues
20. Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and noncancer risk assessment
21. Saturable metabolism and its relation to toxicity
22. What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents?
23. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model
24. Consideration of temporal toxicity challenges current default assumptions
25. Concentration-time relationships for the effects of inhaled trichloroethylene on signal detection behavior in rats
26. A dosimetric analysis of behavioral effects of acute toluene exposure in rats and humans
27. Prospective predictions and validations in anti-cancer therapy
28. Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development
29. Zur geschichte des gaskrieges
30. Symposium on pharmacokinetics/pharmacodynamics in the developing system and impact on risk assessment: Executive summary
31. Pharmacokinetic and pharmacodynamic considerations for chronic hemodialysis
32. Modeling receptor-medicated processes with dioxin: Implications for pharmacokinetics and risk assessment
33. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues
34. Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study
35. A physiologically based pharmacokinetic model for retinoic acid and its metabolites
36. An improved procedure for low-dose carcinogenic risk assessment from animal data
37. Interspecies conversion of kinetically equivalent doses
38. Physiologically based pharmacokinetic modeling and bioactivation of xenobiotics
39. The use of physiologically based pharmacokinetic modeling in risk assessment: A case study with methylene chloride
40. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform
41. A new method for determining allowable daily intakes
42. Calculation of benchmark doses from continuous data
43. Allometry: Body size constraints in animal design
44. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk
45. Computer simulation of cell growth governed by stochastic processes: Application to clonal growth cancer models
46. Biologically based pharmacodynamic models: Tools for toxicological research and risk assessment